Therapy Detail

Therapy Name CBT-101
Therapy Description

CBT-101 is a Met inhibitor that prevents Met phosphorylation and signal transduction to block tumor cell proliferation (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CBT-101 MET Inhibitor 50 CBT-101 is a Met inhibitor that prevents Met phosphorylation and signal transduction to block tumor cell proliferation (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable CBT-101 Phase I Actionable CBT-101 is currently in clinical trial in patients with advanced solid tumors (clinicaltrials.gov, Oct 2018). 10
Clinical Trial Phase Therapies Title Recruitment Status
NCT03175224 Phase I CBT-101 CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation Recruiting